Alzheimer’s Disease cases in the United States are currently estimated to exceed 6 million and are projected to further increase to 13.8 million by 2060 - it is the most common basis for dementia and the sixth leading cause of death [1, 2]. These dire figures highlight the need for additional strategies for Alzheimer’s management. Currently, biomarkers involve only a few known proteins measured in cerebrospinal fluid from lumbar puncture.

To improve routine monitoring and early detection, we aim to develop novel, cost-effective biomarkers with minimal invasiveness and discomfort to facilitate wide screening.

———

[1] Skaria AP. The economic and societal burden of Alzheimer disease: managed care considerations. Am J Manag Care. 2022 Sep;28(10 Suppl):S188-S196. doi: 10.37765/ajmc.2022.89236. PMID: 36197132.

[2] Alzheimer’s Association. Alzheimer’s Disease Facts and Figures. https://www.alz.org/alzheimers-dementia/facts-figures

———

Our research on Alzheimer’s biomarkers is funded by the Alzheimer’s Association.